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http://dx.doi.org/10.1016/j.ccell.2015.05.008SUMMARYStudying mechanisms of malignant transformation of human pre-B cells, we found that acute activation
of oncogenes induced immediate cell death in the vast majority of cells. Few surviving pre-B cell clones
had acquired permissiveness to oncogenic signaling by strong activation of negative feedback regulation
of Erk signaling. Studying negative feedback regulation of Erk in genetic experiments at three different
levels, we found that Spry2, Dusp6, and Etv5 were essential for oncogenic transformation in mouse
models for pre-B acute lymphoblastic leukemia (ALL). Interestingly, a small molecule inhibitor of DUSP6
selectively induced cell death in patient-derived pre-B ALL cells and overcame conventional mechanisms
of drug-resistance.INTRODUCTION
Pre-B acute lymphoblastic leukemia (ALL) represents the most
frequent type of cancer in children and is frequent in adults
as well. Despite greatly improved outcomes for patients over
the past four decades (Bhojwani and Pui, 2013), pre-B ALL
remains one of the leading causes of person-years of life lost
in the United States (362,000 years in 2010; National Center of
Health Statistics; Murphy et al., 2013), which is attributed toSignificance
Targeted therapy of cancer typically focuses on the developme
forming oncogenes below aminimum threshold that is required
the concept that besides the oncogene itself, factors that e
signaling represent a class of therapeutic targets for the treatm
feedback control of Erk at three levels (SPRY2, DUSP6, and ET
for permissiveness of pre-B cells to oncogenic transformation
back regulation of oncogenes as a vulnerability in human ALL
114 Cancer Cell 28, 114–128, July 13, 2015 ª2015 Elsevier Inc.the high incidence of ALL in children. Activating lesions in the
RAS pathway (50%; Zhang et al., 2011) and oncogenic tyrosine
kinases (e.g., BCR-ABL1; 25%) result in hyperactivation of Erk
and other MAP kinases (MAPK). The BCR-ABL1 tyrosine kinase
in Philadelphia chromosome (Ph+) ALL represents the most
frequent oncogene (30% of ALL cases in adults) and also de-
fines the subgroup of patients with the worst clinical outcome
(Fielding, 2010). In addition to classical Ph+ ALL harboring the
BCR-ABL1 rearrangement, recent studies discovered a Ph-likent of agents that will suppress the signaling strength of trans-
to sustain survival and proliferation. In this study, we tested
nable permissiveness of normal pre-B cells to oncogenic
ent of acute lymphoblastic leukemia (ALL). Studying negative
V5), we showed that intact Erk feedback regulation is critical
. Albeit counterintuitive, our findings identify negative feed-
.
subset of ALL that is frequent in children and young adults
(Roberts et al., 2014) and shares central biological and clinical
characteristics with Ph+ ALL. Ph-like ALL is driven by a diverse
spectrum of oncogenic tyrosine kinases and cytokine receptors
(Roberts et al., 2012). Therapy with tyrosine kinase inhibitors
(TKI) in Ph+ or Ph-like ALL typically achieves complete remission
of leukemia. However, these ALL subtypes frequently relapse
under TKI-treatment (Druker et al., 2001).
Lesions that drive oncogenic Erk activation include activating
mutations of NRAS, KRAS, BRAF, and PTPN11 as well as
inactivating mutations of NF1 (Zhang et al., 2011). Lesions in
the Erk pathway are frequently found in relapse ALL samples
and are drivers of ALL relapse (Irving et al., 2014). Activated
Erk translocates to the nucleus and drives transcriptional activa-
tion of proliferation via FOS, JUN, and MYC as well as its own
negative feedback at three levels: (1) The sprouty family
signaling inhibitor SPRY2 negatively regulates activation of
RAS (Hanafusa et al., 2002). (2) The dual specificity phospha-
tase 6 (DUSP6) dephosphorylates Erk (Tanoue et al., 2000).
And (3) through translocation to the nucleus, Erk cooperates
with PEA3 Ets transcription factors including ETV1, ETV4, and
ETV5 that function as transcriptional activators of DUSP6 and
SPRY2 (Chi et al., 2010; Znosko et al., 2010; Hollenhorst
et al., 2011).
Targeted therapy of cancer typically focuses on the develop-
ment of agents that withdraw a transforming oncogene that
cancer cells have become addicted to. In this study, we tested
the concept that besides the oncogene itself, additional factors
confer permissiveness to oncogenic signaling and enable a
normal cell to engage with and tolerate an oncogenic level of
signaling strength. These factors would represent vulnerabilities
that can be leveraged in anti-cancer therapies and, hence, be
considered as a class of therapeutic targets.
RESULTS
Our hypothesis was based on our finding that acute activation
of oncogenes (e.g., BCR-ABL1 and NRASG12D) induced cell
death in the vast majority of human pre-B cells (Figures 1A,
S1A, and S1B). Only a small fraction survived acute activation
of oncogene signaling and eventually gave rise to malignant
transformation after a delay of more than 3 weeks. A phenotypic
comparison at the gene expression level between human pre-B
cells with acute activation of BCR-ABL1 (1 day) and complete
transformation by BCR-ABL1 (25 days) revealed that trans-
formed pre-B ALL clones evolved high expression levels of
negative regulators of Erk, including DUSP6, ETV5, and SPRY2
(Figures 1B and 1C). While activation of BCR-ABL1 in the
parental pre-B cell culture caused cell death, the transformed
pre-B cell clones were addicted to BCR-ABL1 after 25 days
and had acquired sensitivity to TKI. Interestingly, TKI-treatment
for 1 hr (25 days-Off) was sufficient to erase high expression
levels of negative control molecules (Figure 1B).
Pre-B Cells in BCR-ABL1-Transgenic Mice Are Not
Readily Permissive to Oncogenic Transformation
In BCR-ABL1-transgenic mice, all pre-B cells carry the BCR-
ABL1 transgene. However, leukemia invariably develops only
from a very small number of pre-B cell clones as a monoclonaldisease in most cases (Voncken et al., 1992). The BCR-ABL1-
transgenic mouse model suggests that the vast majority of
pre-B cells are not readily permissive to oncogenic transforma-
tion. BCR-ABL1-transgenic mice gave rise to overt pre-B ALL
(accumulation of peripheral blood CD19+ surface Ig blasts)
only after about 90 days and BCR-ABL1 mRNA levels remained
undetectable in the bone marrow until about 60 days of age
(Figure 1D). Single-cell RT-PCR analysis revealed that the
BCR-ABL1-transgene was transcriptionally silent in 11 of 12
pre-B cells sorted from pooled bone marrows of disease-free
‘‘pre-leukemic’’ BCR-ABL1-transgenic mice at a young age
(n = 3). In BCR-ABL1-transgenic mice with full-blown leukemia,
virtually all bone marrow pre-B cells expressed the BCR-ABL1-
transgene and became addicted to the oncogene: subsequent
TKI treatment selectively killed these cells and spared pre-B cells
carrying a transcriptionally silent BCR-ABL1-transgene (Fig-
ure 1E). Comparing pre-leukemic and fully transformed pre-B
cells from BCR-ABL1-transgenic mice, we found that leukemic
transformation was paralleled by strong activation of genes
encoding negative control of Erk (Dusp6, Spry2, and Etv5;
Figure 1F). Expression of these molecules was sensitive to
TKI-treatment in vivo. Based on these findings, we hypothesize
that activation of BCR-ABL1 and other oncogenes in pre-B cells
imposes selective pressures in favor of clones that have evolved
robust negative control of Erk. In the absence of robust negative
control, pre-B cells are not permissive to oncogene activation
and are counterselected from the pre-leukemic repertoire in
BCR-ABL1-transgenic mice (Figure 1E).
Erk Negative Control Is Selectively Activated
in Human Pre-B ALL Cells
Recent studies found that negative feedback regulators of Erk
(DUSP6, ETV5, and SPRY2) are frequently inactivated in solid
tumors (Xu et al., 2005; Shaw et al., 2007; Schutzman andMartin,
2012; Wong et al., 2012) and mature B cell lymphoma (Frank
et al., 2009) and have an important role as tumor suppressors
in attenuating oncogenic signaling (Courtois-Cox et al., 2006).
Surprisingly, however, primary samples from patients with pre-
B ALL (n = 83) showed significantly lower levels of CpG methyl-
ation in the promoters of DUSP6, ETV5, and SPRY2 compared
to normal pre-B cells (Figure 1G). These results suggest that
pre-B ALL cells, unlike normal pre-B cells, are poised to express
negative regulators of Erk. To measure activity of Erk negative
regulation in a larger cohort of patient-derived samples, reverse
phase protein array (RPPA) data from a clinical trial for
adults with pre-B ALL were studied for protein levels of
DUSP6 and phospho-ERK-T202/Y204. RPPA measurements re-
vealed a strong positive correlation between expression levels
of phospho-ERK-T202/Y204 and its negative regulator DUSP6
(Figure 1H). RPPA protein levels for DUSP6 also correlated
with activity of other MAPK including p38a (MAPK14) and MEK
(MAP2K1; Figure S1C). Western blot analyses confirmed that
patient-derived pre-B ALL cells express DUSP6, SPRY2, and
ETV5 at much higher levels than bone marrow pre-B cells (Fig-
ure 1I). Consistent with dynamic changes of mRNA levels during
BCR-ABL1-mediated transformation of human (Figure 1B) and
mouse pre-B cells (Figure 1F), high protein levels of negative
regulators were sensitive to Imatinib treatment in human Ph+
ALL cells (Figure 1J). Likewise, MEK kinase inhibition not onlyCancer Cell 28, 114–128, July 13, 2015 ª2015 Elsevier Inc. 115
Figure 1. Activation of Negative Control Correlates with Pre-B Cell Transformation
(A) Human bone marrow pre-B cell cultures were transduced with retroviral BCR-ABL1GFP and GFP EV. The fractions of GFP-expressing cells were measured by
flow cytometry and fold-change of GFP+ cells and are depicted (y axis). The x axis represents days after transduction. The error bars represent SD.
(B) Gene expression changes upon acute BCR-ABL1 activation (TKI-washout; 1 day), full transformation of pre-B cells (25 day), and acute BCR-ABL1 kinase
inhibition (TKI readdition; 25 day-Off) were monitored by microarray analysis.
(C) Schematic of negative feedback control of Erk signaling molecules studied here.
(D) Progressive leukemic transformation of pre-B cells in BCR-ABL1-transgenic mice was monitored by measurement of BCR-ABL1mRNA levels and peripheral
blood B cell precursors (CD19+ surface Ig) relative to the mRNA levels of Spry2, Dusp6, and Etv5.
(E) Single pre-B cells from the bone marrow of wild-type controls, young BCR-ABL1-transgenic mice (no detectable disease), BCR-ABL1-transgenic mice with
overt leukemia before and after in vivo treatment with Nilotinib (TKI) were sorted into PCR tubes and the BCR-ABL1 transcripts were amplified by RT-PCR.
The positive cells were depicted as red circles.
(F) Gene expression changes during progressive malignant transformation of pre-B cells in BCR-ABL1-transgenic mice are depicted as a heatmap.
(G) Results of CpG methylation analyses are shown for promoters of SPRY2, DUSP6, and ETV5 in CD19+ bone marrow pre-B cells from healthy donors (n = 12)
and bone marrow biopsies from patients with Ph+ ALL (n = 83). The p values were calculated from two-sided Mann-Whitney Wilcoxon test.
(H) RPPA data from pre-B ALL samples in the adult MDACC 1983–2007 clinical trial for ERK phosphorylation (T202/Y204) and DUSP6 protein expression were
plotted (n = 126). The correlation coefficient was calculated using the Pearson correlation coefficient.
(legend continued on next page)
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abolished Erk activity, but also reduced DUSP6 protein levels by
4- to 25-fold (Figure 1K).
Robustness of Erk Negative Control Is a Predictor
of Poor Clinical Outcome in B Cell-Lineage,
but Not Myeloid Leukemia
Previous work demonstrated that negative feedback inhibition of
Erk signaling induces oncogene-induced senescence and repre-
sents a barrier against malignant transformation (Courtois-Cox
et al., 2006), which is disabled in many types of cancer (Pratilas
et al., 2009; Frank et al., 2009). In human pre-B ALL, however,
negative control of Erk is constitutively active (Figure 1I). We
therefore tested whether activity of this pathway correlates
with the course of disease and clinical outcome of patients
with pre-B ALL. To this end, we studied DUSP6 mRNA levels
as a potential predictor of outcome for adults with Ph+ ALL, using
acute myeloid leukemia (AML) patients as a reference. For these
analyses, patients were separated into two groups based on
higher or lower than median mRNA levels of DUSP6 at the time
of diagnosis. In AML, higher than median levels of DUSP6 asso-
ciated with a trend toward longer overall survival (Figure 2A),
however, in contrast, higher than median DUSP6 levels strongly
correlated with shorter overall survival for adults with pre-B ALL
(Figure 2A). Multivariate analyses using achievement of com-
plete remission (CR) as an established risk factor, showed
that high DUSP6mRNA levels represent independent predictors
of clinical outcome in adults with pre-B ALL (Figure 2A). We
then combined each three activators (MAPK; MAPK1, NRAS,
and MAP2K1) and negative regulators (DUSP; DUSP6, SPRY2,
and ETV5) into a six-gene outcome predictor (Figure 2B). The
potential usefulness of the DUSP-MAPK outcome predictor is
exemplified based on two cohorts: Among adults with Ph+
ALL, none of the patients with DUSPHigh/MAPKLow profile sur-
vived 15 months after diagnosis, whereas 50% of patients
with DUSPLow/MAPKHigh were still alive 8 years after diagnosis
(Figure 2B). Similarly, in the pediatric high-risk ALL trial, patients
with a DUSPLow/MAPKHigh profile represented a group with a
particularly favorable outcome (Figure 2B). Multivariate analyses
confirmed that the DUSP/MAPK profile represents an indepen-
dent predictor of clinical outcome (Figure S2). In contrast
to B cell-lineage ALL, the combined analysis of DUSP-MAPK
profiles had the opposite outcome in AML patients (Figure 2B).
These findings suggest that high expression levels of Erk
negative regulators represent a powerful, albeit B cell lineage-
specific, biomarker with potential uses in risk stratification of
pre-B ALL patients.
To test potential divergent lineage-specific functions of
DUSP6, we isolated bone marrow from Dusp6/ mice (Maillet
et al., 2008) and wild-type controls and transformed B cell line-
age and myeloid progenitor cells with BCR-ABL1 (Figure 2C).
Interestingly, levels of both Erk activity and DUSP6 expression
differed between B cell and myeloid lineage leukemia cells,
suggesting distinct lineage-specific Erk activity regulation (Fig-(I) Western blot analysis for expression of DUSP6, SPRY2, and ETV5 in normal CD
shown with b-actin as loading control.
(J) Western blot analysis for expression of DUSP6, SPRY2, and ETV5 in Ph+ pre
(K) Patient derived ALL cells were treated with or without the MEK inhibitor PD
performed using b-actin as loading control. See also Figure S1.ure 2D). For colony forming assays, Dusp6+/+ and Dusp6/
B cell lineage and myeloid lineage leukemia cells were plated
in methylcellulose. Consistent with a role of DUSP6 as a tumor
suppressor in multiple types of cancer (Courtois-Cox et al.,
2006; Pratilas et al., 2009; Frank et al., 2009), colony formation
of Dusp6/ myeloid leukemia was increased compared to
wild-type controls (Figure 2E). In contrast, colony formation of
Dusp6/ B cell lineage leukemia was reduced (Figure 2E), sup-
porting the concept that, unlike other types of cancer, DUSP6
enables malignant transformation in B cell lineage ALL.
DUSP6-Mediated Negative Control of Erk Signaling
Is Essential for NRASG12D-Mediated Pre-B Cell
Transformation
To determine the significance of Erk negative regulation in RAS-
driven ALL in a genetic experiment, we transducedDusp6+/+ and
Dusp6/ IL7-dependent pre-B cells with a doxycycline-induc-
ible vector system for regulatable expression of oncogenic
NRASG12D. While expression of NRASG12D was able to transform
Dusp6+/+ pre-B cells and increase colony formation, NRASG12D
failed to transform or induce colony formation of Dusp6/ pre-
B cells (Figure 3A). Induction of NRASG12D caused a moderate
increase in Erk phosphorylation in the presence of Dusp6. In
Dusp6/ pre-B cells, Erk is constitutively active and massively
increased upon induction of NRASG12D (Figure 3B). Reconstitu-
tion of Dusp6/ NRASG12D pre-B cells with the wild-type
DUSP6, but not catalytically inactive DUSP6C293S, corrected
massive hyperactivation of Erk (Figures 3C and 3D). Collectively,
these findings establish that DUSP6 is required to calibrate
Erk signaling downstream of oncogenic NRASG12D and that
DUSP6 is essential for RAS-driven B cell lineage ALL. Interest-
ingly, acute activation of NRASG12D in Dusp6+/+ pre-B cells
caused a minor increase of cellular senescence and had no
significant impact on cell viability. In the absence of Dusp6,
however, activation of NRASG12D caused massive senescence
and acute toxicity (Figures 3E and 3F), highlighting the critical
importance of DUSP6-dependent negative regulation in buff-
ering Erk signal strength in transformed murine pre-B cells.
These findings are also relevant to human pre-B ALL. Transduc-
tion of KRASG12V- and MLL-AF4-driven human ALL cells with
small hairpin RNA vectors against DUSP6 resulted in 50%
reduction of DUSP6. While the resulting increase in Erk activity
wasminor, it was sufficient to significantly reduce colony forming
capacity of the two pre-B ALL cases (Figures 3G and 3H). These
findings suggest that human ALL cells are uniquely sensitive to
even small imbalances in Erk signaling.
Transduction of Dusp6+/+ pre-B cells with NRASG12D induced
leukemic transformation and fatal disease in transplant
recipients (Figure 3I). Dusp6/ pre-B cells transduced with
NRASG12D, however, failed to initiate lethal leukemia in trans-
plant recipients (Figure 3I). In multiple tumor types, DUSP6-
mediated feedback inhibition of Erk induces cellular senes-
cence and represents a barrier against RAS-driven malignant19+ bone marrow pre-B cells (n = 5) and patient-derived pre-B ALL (n = 10) are
-B ALL cases (±Imatinib 10 mmol/l) is shown using b-actin as loading control.
0325901 for 2 hr. Western blot for DUSP6 and total and phospho-ERK were
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Figure 2. B Cell-Specific Role of Erk-Negative Control in Leukemia
(A) DUSP6 mRNA levels were studied in adult patients with Ph+ ALL (ECOG 2993; n = 54) at the time of diagnosis as a potential predictor of outcome. The AML
patient samples (AML TCGA; n = 167) were similarly studied as a reference. The patients were separated into two groups based on higher or lower than median
mRNA levels ofDUSP6. Also a multivariate analysis was performed usingDUSP6mRNA levels and achievement of CR as an established risk factor. The p values
were calculated from log-rank test.
(B) Expression levels of three activators (MAPK;MAPK1, NRAS, andMAP2K1) and three negative regulators (DUSP; DUSP6, SPRY2, and ETV5) of Erk signaling
were combined into a six-gene outcome predictor. The DUSP-MAPK outcome predictor was used for adult patients with Ph+ ALL (ECOG E2993; n = 55) and
pediatric patients with high-risk ALL (COGP9906; n = 191). The patients with AML (AML TCGA; n = 167) were similarly analyzed as a reference. The p values were
calculated from log-rank test.
(C–E) B cell lineage and myeloid progenitor cells from Dusp6/ and wild-type mice were transformed with BCR-ABL1. The transformed cells were analyzed for
their expression of lineage cell surfacemarkers by flow cytometry (C); their exppression of DUSP6, total and phosphorylated ERK1/2, and BCR-ABL1 by western
blot (D); and colony formation capacity plated in methylcellulose (E). b-actin was used as loading control in the western blot. The scale bars represent 1 mm. The
error bars represent SD, and p values were calculated from t test. See also Figure S2.
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transformation (Courtois-Cox et al., 2006). Our findings here
reveal that DUSP6-mediated negative regulation of Erk repre-
sents a critical lineage-specific vulnerability in B cell lineage ALL.
Genetic Analysis of Erk Negative Control in Pre-B Cell
Transformation
These findings suggest that effector molecules of Erk negative
control may represent a class of therapeutic targets for the
treatment of human B cell lineage ALL. For this reason, we
measured functional consequences of Dusp6- and Etv5-defi-
ciency as well as Cre-mediated deletion of Spry2 in mouse
models of pre-B ALL based on NRASG12D and BCR-ABL1-medi-
ated transformation. Bone marrow pre-B cells from Dusp6/
(Maillet et al., 2008), Etv5/ (Chen et al., 2005), and Spry2fl/fl
(Shim et al., 2005) mice and wild-type controls were trans-
formed with retroviral NRASG12D or BCR-ABL1. In addition,
Spry2fl/fl pre-B ALL cells were transduced with a 4-hydroxy
tamoxifen (4-OHT) inducible form of Cre for deletion of LoxP-
flanked Spry2 alleles.
Loss of Dusp6, Etv5, or Spry2 caused a number of promi-
nent gene expression changes, many of which were shared
among the three (Figures 4A and S3A). For instance, loss of
Dusp6, Etv5, or Spry2 commonly resulted in increased expres-
sion of the p53-related tumor suppressors Cdkn2a (Arf),
Btg2, and Cd82 (Figure 4A). Pre-B ALL cells lacking robust
Erk negative control acquired multiple determinants of
myeloid, monocytic, and mast cell lineages (e.g., Mcpt2, IgE
Fc receptors, Ccl2, Ccl3, and Csfr2b) at the expense of pre-
B cell specific molecules (Ighm, Ms4a1, Igh, Igk, Il7r, Dntt,
Bank1, Rag1, Rag2, and Vpreb1; Figure 4A). These findings
are consistent with lineage-specific effects of Erk negative
control. Together with the phenotypic shift of Dusp6/ pre-
B ALL cells to a myeloid/mast cell gene expression pattern,
these findings suggest that pre-B ALL cells are dependent
on robust Erk negative control, whereas myeloid leukemia cells
proliferate more vigorously in its absence (Figures 2D, S3B,
and S3C). In support of the concept that pre-B ALL cells are
uniquely sensitive to hyperactive Erk, a recent study identified
a checkpoint at the pre-B cell stage that negatively selects
normal pre-B cell clones with elevated Erk activity (Limnander
et al., 2011).
Previous work demonstrated that Erk-mediated serine-
phosphorylation activates and stabilizes p53 (Fuchs et al.,
1998). Compared to wild-type pre-B ALL cells, Dusp6/and
Etv5/ pre-B ALL cells expressed higher p53 protein levels
(Figure 4B). 4-OHT-mediated induction of Cre in Spry2fl/fl
pre-B ALL cells resulted in deletion of Spry2 and rapid pre-B
ALL cell death in parallel with hyperactive Erk signaling (Fig-
ures 4C–4E). The decrease in the number of cells in S phase
likely reflects induction of cell death upon deletion of Spry2
(Figure 4F). We confirmed that Erk-hyperactivation, resulting
from loss of SPRY2 function, compromised pre-B ALL leuke-
mogenesis in vivo. To this end, Spry2fl/fl pre-B ALL cells
were transduced with either 4-OHT inducible Cre or an empty
vector control (EV), labeled with firefly luciferase, and injected
into sublethally irradiated nonobese diabetic (NOD)/severe
combined immunodeficiency (SCID) recipient mice. Spry2fl/fl
leukemia cells in Cre and EV groups were normalized for equal
numbers (1 million) and luciferase signal intensity (Figure 4G)prior to injection. Consistent with in vitro findings, deletion of
Spry2 delayed leukemia onset in vivo and prolonged overall
survival of NOD/SCID recipient mice. Since Erk activity in-
creases levels of reactive oxygen species (ROS) via phosphor-
ylation of p47Phox-S359 (Dang et al., 2006), we examined the
role of Erk negative control in ROS-regulation. Genetic deletion
of Dusp6, Etv5, and Spry2 in BCR-ABL1-transformed pre-B
ALL cells caused significant accumulation of ROS (Figure 4H).
In parallel with increased p53 protein levels in Dusp6/ and
Etv5/ pre-B ALL cells, leukemia cells lacking robust Erk
negative control lost colony forming ability in methylcellulose
(Figure 4I).
DUSP6-Deficient Pre-B Cells Are Not Permissive
to Transformation by BCR-ABL1
We next tested how calibration of Erk activity by DUSP6 and
SPRY2 activity affects malignant transformation of pre-B cells.
To test the role of DUSP6, we performed a TKI-washout exper-
iment for acute activation of BCR-ABL1 in pre-B cells. Dusp6+/+
and Dusp6/ pre-B cells were propagated in the presence
of IL7 and saturating concentrations of Imatinib. IL7-dependent
Dusp6+/+ and Dusp6/ pre-B cells were transduced with
BCR-ABL1GFP-vectors in the continued presence of Imatinib.
On the second day after transduction, IL7 was removed from
cell cultures. As expected, subsequent washout of Imatinib
(red arrow; Figure 4J) and inducible activation of BCR-ABL1
resulted in IL7-independence and leukemic transformation of
Dusp6+/+ BCR-ABL1GFP pre-B cells. In contrast to Dusp6+/+
cells, Dusp6/ pre-B cells failed to undergo BCR-ABL1-medi-
ated transformation and did not outgrow nontransduced cells
in the absence of IL7 (Figure 4J). In addition, Dusp6/ pre-B
ALL cells were more sensitive to acute BCR-ABL1 tyrosine
kinase inhibition by Imatinib, compared to wild-type controls
(Figure 4K). Likewise, Cre-mediated deletion of Spry2 sensi-
tized pre-B ALL cells to acute BCR-ABL1 tyrosine kinase
inhibition (Figure 4L). Collectively, genetic experiments in
NRASG12D- and BCR-ABL1-driven pre-B ALL demonstrate
that robust negative feedback control of Erk signaling is critical
to balance acute fluctuations of oncogenic signaling strength
(e.g., washout and treatment with Imatinib). Previous work
established that SPRY2, DUSP6, and ETV5 have important
tumor suppressor functions in multiple types of cancer, which
is in agreement with our findings in myeloid Dusp6/ leukemia
cells (Figure 2D). In contrast, however, pre-B ALL cells are
uniquely dependent on the robust negative feedback control
of Erk signaling.
Pharmacological Inhibition of DUSP6 in Human Pre-B
ALL Cells
To explore potential targeting of negative regulatory signaling
in human pre-B ALL, we tested a recently developed selective
small molecule inhibitor of DUSP6, 2-benzylidene-3-(cyclohex-
ylamino)-1-Indanone hydrochloride (BCI; Figure 5A; Vogt et al.,
2003; Molina et al., 2009). As predicted, treatment of patient-
derived Ph+ ALL cells with BCI (5 mmol/l) resulted in hyper-
activation of Erk within 1 hr (Figures 5B–5D). Interestingly,
BCI-induced hyperactivation of Erk was paralleled by strong
increases of ROS levels (Figure 5E). Small molecule inhibition
of DUSP6 induced massive dephosphorylation at multipleCancer Cell 28, 114–128, July 13, 2015 ª2015 Elsevier Inc. 119
Figure 3. Dusp6 Negative Control of Erk Is Essential for NRASG12D-Mediated Pre-B Cell Transformation
(A) Dusp6+/+ and Dusp6/ IL7-dependent pre-B cells were transduced with a doxycycline-inducible vector system for regulatable expression of oncogenic
NRASG12D. The cells were plated in methylcellulose to study colony formation in the presence and absence of NRASG12D. The scale bars represent 1 mm. The
p value was calculated from t test.
(B) Western blot analysis on NRASG12D transduced cells for NRAS and total and phosphorylated ERK1/2 using b-actin as loading control.
(C) NRASG12D transduced Dusp6+/+ and Dusp6/ pre-B cells were transduced with either EV or wild-type DUSP6 and studied by western blot.
(D) NRASG12D transduced Dusp6/ pre-B cells were transduced with EV, wild-type DUSP6, or catalytically inactive (DUSP6C293S) and studied by western blot.
(E) Dusp6+/+ and Dusp6/ pre-B cells were induced to express NRASG12D and stained for senescence-associated b-galactosidase activity (pH 5.5) to label
senescent cells. The scale bars represent 50 mm. The p value was calculated from t test.
(F) Viability of Dusp6+/+ and Dusp6/ pre-B cells was measured upon induction of NRASG12D.
(legend continued on next page)
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phosphotyrosines as determined by global phospho-tyrosine
analysis (Figure 5F). The net loss of tyrosine-phosphorylation
events suggests that the initial peak of Erk hyperactivation
is followed by loss of permissiveness to oncogenic tyrosine
kinase signaling (BCR-ABL1; Figure 5F).
Our initial results indicated that pre-B cells are only permissive
to strong oncogenic signaling (e.g., BCR-ABL1, NRASG12D) in
the presence of robust negative control. In young BCR-ABL1-
transgenic mice, pre-B cells carry a silent BCR-ABL1 oncogene
until they have evolved robust negative regulation (Figures
1D–1F). Here, we observed that small molecule inhibition of
DUSP6 compromises negative control of Erk signaling and oblit-
erates oncogenic tyrosine kinase signaling (Figures 5F and 5G).
Treatment with BCI reduced both total BCR-ABL1 and phos-
phorylation of Y412 in the BCR-ABL1 activation loop (Figure 5G),
which reflects loss of catalytic activity (Hantschel and Superti-
Furga, 2004). Interestingly, inhibition of DUSP6 abruptly reduced
phosphorylation of RPS6-S235/236, which represents a down-
stream substrate of PI3K-Akt signaling (Figure 5G). RPS6
dephosphorylation clearly precedes reduction of BCR-ABL1
expression and activity and, therefore, likely represents an inde-
pendent event. Since DUSP6 inhibition (BCI, 2 mmol/l) resulted in
BCR-ABL1 tyrosine kinase inactivation, we tested whether BCI
treatment cooperates with BCR-ABL1 TKI and found strong syn-
ergistic activity with Imatinib (Figure 5H). BCI induced cell death
in BCR-ABL1 ALL cells (half maximal inhibitory concentration
[IC50] 2.1 mmol/l), and subtherapeutic doses of Imatinib
(0.5 mmol/l) enhanced sensitivity of the leukemia cells to BCI
(IC50 0.7 mmol/L; Figure 5H).
Pharmacological Inhibition of DUSP6 in Ph+ ALL Cells
Induces p53-Mediated Cell Death
Studying pre-B ALL cells from patient-derived bone marrow
biopsies, we confirmed that BCI induced strong upregulation
of both Arf and p53 to a comparable extent as in murine
Dusp6/ pre-B ALL cells (Figures 6A and 6B). In a genetic
experiment based on inducible Cre-mediated deletion of
Cdkn2a or Trp53 in mouse BCR-ABL1 ALL cells, we demon-
strated that BCI mediates its cytotoxic effect in part through
p53 and Arf (Figure 6C). These findings raise the possibility
that BCI-mediated Erk-hyperactivation causes serine-phos-
phorylation and stabilization of p53 (Fuchs et al., 1998), which
then contributes to the selective toxic effect of BCI in pre-B
ALL cells. Previous work demonstrated that Erk signaling could
activate the DNA damage response via phosphorylation of
ATM-S1981 and CHK2-T68 (Golding et al., 2007). Therefore,
pre-B ALL cells from two patients (BLQ5 and LAX2) were
treated with or without BCI and phosphorylation levels of
ERK1/2-T202/Y204, ATM-S1981, and CHK2-T68 were measured.
Interestingly, BCI-induced Erk-hyperactivation mimics the
function of a DNA damage sensor and induced activation of(G) Knockdown of DUSP6 in human ALL cells with short hairpin (sh)RNA. The kno
western blot.
(H)KRASG12V- andMLL-AF4-driven human ALL cells were transducedwith shRNA
study their colony formation ability. The scale bars represent 1 mm. The p value
(I) Dusp6+/+ and Dusp6/ pre-B cells were induced to express NRASG12D, lab
recipients (n = 7 per group). The leukemia burden was measured by luciferase b
Meier analysis. The p value was calculated by log-rank test. All of the error barsthe DNA damage response including ATM and CHK2, upstream
of p53 (Figure 6D).
BCI-induced cell death was in part rescued by the ROS scav-
enger catalase (Figure 6E) and further increased by the gluta-
thione-S-transferase inhibitor BSO (Figure S4), indicating that
ROS is in part responsible for induction of cell death in patient-
derived Ph+ ALL cells. The nicotinamide adenine dinucleotide
phosphate (NADPH) oxidase complex, activated by its regula-
tory subunit p47phox, represents an important source of ROS
production and is activated by Erk-dependent phosphorylation
of p47Phox-S359 (Dang et al., 2006). Compared to normal bone
marrow pre-B cells, p47phox levels and activation are signifi-
cantly lower in patient-derived Ph+ ALL cells (Figure 6F), sug-
gesting that Ph+ ALL cells are less permissive to p47phox-driven
ROS production. The effect of BCI on ROS accumulation in part
depends on p47phox function, since p47phox-deficient (Ncf1/)
mouse leukemia cells showed lower levels of ROS accumulation
(Figure 6G) and are significantly less sensitive to BCI (Figure 6H).
DUSP6 Small Molecule Inhibition Can Overcome
Drug-Resistance in Relapse Pre-B ALL
To test whether oncogenic activity of Erk confers selective sensi-
tivity to DUSP6 inhibition, we studied patient-derived pre-B ALL
cells that were isolated at the time of diagnosis (LAX7) and at the
time of relapse (LAX7R), when pre-B ALL cells had acquired a
KRASG12V mutation (Figure 7A). As a likely consequence of the
acquired KRASG12V mutation, we found oncogenic activation
of Erk in LAX7R, but not LAX7 cells (Figure 7B). In the absence
of detectable baseline activity of Erk, DUSP6 inhibition had no
biochemical effects on LAX7 (KRAS wild-type). In contrast,
constitutive Erk activity in the KRASG12V mutant LAX7R cells
was strongly increased by treatment with BCI. Relapse pre-B
ALL clones typically acquire a high level of drug-resistance
during the initial course of treatment (Bhojwani and Pui, 2013).
However, comparing KRAS wild-type LAX7 cells and KRASG12V
mutant LAX7R cells, the relapse ALL cells had acquired sensi-
tivity to BCI (Figure 7C). Given that ALL clones frequently acquire
oncogenic lesions in the RAS pathway leading to hyperactivation
of Erk (Irving et al., 2014), these findings suggest that small
molecule inhibition of DUSP6 may be useful to overcome drug-
resistance in these patients.
Outcomes of DUSP6 Small Molecule Inhibition Depend
on Apoptotic Thresholds of Erk Signaling
The selective effects of BCI on RASmutant ALL cells with hyper-
active Erk suggest that the BCI-induced toxicity is linked to a
threshold of Erk signaling that has to be overcome to trigger
apoptosis. To directly test this hypothesis, we experimentally
lowered the ‘‘buffer setpoint’’ for Erk signaling and negative
feedback control in patient-derived pre-B ALL cells expressing
hyperactive Erk. To this end, LAX7R were cultured in theckdown efficiency and changes in ERK1/2 phosphorylation were measured by
vectors against DUSP6 or scrambled controls and plated inmethylcellulose to
s were calculated from t test.
eled with firefly luciferase, and injected into sublethally irradiated NOD/SCID
ioimaging and overall survival of the mouse recipients was plotted by Kaplan-
represent SD.
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Figure 4. Genetic Analysis of Erk Negative Control in Pre-B ALL Cells
(A) Bone marrow pre-B cells from Dusp6/, Etv5/, and Spry2fl/fl mice and wild-type controls were transformed with BCR-ABL1. Spry2fl/fl leukemia cells were
retrovirally transduced with a 4-OHT inducible Cre for deletion of LoxP-flanked Spry2 alleles. The microarray analyses depict common gene expression changes
upon loss of Dusp6, Etv5, and Spry2 in pre-B ALL cells.
(B) Western blot analysis shows expression levels of p53 and p21 in BCR-ABL1 pre-B ALL cells lacking expression of Dusp6 and Etv5.
(C) Inducible activation of Cre in Spry2fl/fl BCR-ABL1 pre-B ALL cells results in loss of SPRY2 expression and hyperactivation of Erk.
(D) Apoptosis was measured by flow cytometry (Annexin V+).
(E) Spry2fl/fl ALL cells were retrovirally transduced with 4-OHT-inducible Cre and cell viability was monitored under cell culture conditions over time following
4-OHT addition.
(legend continued on next page)
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presence or absence of the MEK inhibitor PD0325901, the con-
centration of which was gradually increased from 0.1 nmol/l over
2 weeks to a final concentration of 50 nmol/l. At that time,
PD0325901-treated cells had fully adapted to low levels of
Erk signaling with similar viability and proliferation characteris-
tics as vehicle-treated cells (Figure S5A). After washout of
PD0325901 (Erk rebound), LAX7R cells were treated for 2 days
with BCI at various concentrations and viability was measured.
The ‘‘Erk-rebound’’ setting after initial lowering of Erk signaling
thresholds (PD0325901-pretreatment) sensitized pre-B ALL
cells to subsequent DUSP6 inhibition and reduced the IC50 for
BCI from 2.3 mmol/l to 0.4 mmol/l (Figures 7D and 7E).
As expected, BCI selectively induced toxicity in a panel of hu-
man pre-B ALL cell lines expressing hyperactive Erk (Figure 7F).
Given that Erk activity is usually low in normal cells, selective
toxicity in cells expressing hyperactive Erk suggests a therapeu-
tic window for pharmacological DUSP6 inhibition in pre-B ALL.
For this reason, we tested the efficacy of BCI in a panel of five
Ph+ ALL xenografts from patients who relapsed during ongoing
TKI-therapy (Figures 7G and 7H). While Imatinib-treatment did
not significantly affect the viability of Ph+ ALL cells from patients
at the time of relapse, BCI achieved profound effects at the same
dose levels (Figure 7G). Importantly, BCI was equally effective
against Ph+ ALL cells carrying the BCR-ABL1T315I mutation,
which confers Imatinib resistance (BLQ5 and LAX2; Figure 7G).
To test whether DUSP6 inhibition can overcome Imatinib resis-
tance of Ph+ ALL cells in an in vivo setting, we labeled BCR-
ABL1T315I Ph+ ALL cells from two patients (LAX2 and BLQ5)
with firefly luciferase and injected them into sublethally irradiated
(2.5 Gy) NOD/SCID mice. There were two different treatment
schedules that were tested to examine the effect of BCI on leu-
kemia-initiation (cells were treated for 4 hr before injection; Fig-
ures 7I and 7J) and on established leukemia (treatment started
when leukemic expansion was visible by luciferase bioimaging;
Figure S5B). For the latter, mice were treated with either vehicle,
the second generation BCR-ABL1 TKI Nilotinib, or BCI. Mirroring
drug-resistance in patients, treatment with Nilotinib did not
significantly extend the lifespan of the transplanted mice (Fig-
ure S5B). By contrast, treatment with BCI significantly prolonged
overall survival of the mice carrying established leukemia (Fig-
ure S5B). In summary, transplant studies of patient-derived
Ph+ ALL validated small molecule inhibition of DUSP6 and
hyperactivation of Erk as a potentially useful approach for the
treatment of TKI-resistant (e.g., BCR-ABL1T315I) Ph+ ALL.(F) Proliferation and cell cycle phases were measured by BrdU incorporation. Th
(G) Spry2fl/fl pre-B ALL cells were labeled with firefly luciferase. There were two m
were treatedwith 4-OHT and subsequently injected into sublethally irradiated NOD
EV-transduced Spry2fl/fl leukemia cells were verified prior to injection. The Cre-de
The p value was calculated by log-rank test.
(H) Dusp6-, Etv5-, and Spry2-deficient and wild-type BCR-ABL1 pre-B ALL cells
based on intracellular levels of ROS. The mean fluorescence intensities for DCF
(I) Each 10,000 Dusp6-, Etv5-, and Spry2-deficient and wild-type BCR-ABL1 pre
numbers of colonies are shown. The scale bars represent 0.5 mm. The p values
(J)Dusp6/ andDusp6+/+ bonemarrowpre-B cellswere isolated andpropagated
Imatinib (1 mmol/l) was added andpre-B cellswere transducedwith BCR-ABL1GFP.
Uponwashout of Imatinib and IL7 (arrow), the fractionofBCR-ABL1GFP+ cellswerep
(K) Sensitivity to Imatinib was measured in Dusp6/ and Dusp6+/+ pre-B ALL ce
(L) Sensitivity to Imatinib was measured in Spry2fl/fl BCR-ABL1 pre-B ALL cells w
Figure S3.DISCUSSION
In a wide range of solid tumors, acute hyperactivation of onco-
genes including BRAFV600E, Ras, and Myc can cause onco-
gene-induced senescence (Serrano et al., 1997; Michaloglou
et al., 2005), which represents an important barrier against
malignant transformation. Strong activation of negative feed-
back rather than hyperactive Erk signaling itself is responsible
for induction of senescence and growth arrest in solid tumors
(Courtois-Cox et al., 2006). In agreement with this concept,
negative feedback regulation is typically disabled in advanced
BRAFV600E- and Ras-driven solid tumors (Pratilas et al.,
2009) and gene encoding negative feedback regulators of
Erk are frequently deleted, mutated, or hypermethylated in
solid tumors and mature B cell lymphoma. Likewise, our find-
ings in Dusp6/ myeloid leukemia support the concept that
negative regulators of Erk have an important role as tumor
suppressors in attenuating oncogenic signaling (Courtois-
Cox et al., 2006).
In contrast to the established tumor suppressor role of nega-
tive feedback in solid tumors, our study demonstrates that in
pre-B ALL, robust negative feedback control of Erk is critical
for oncogenic transformation and development of fatal disease.
These findings suggest that negative control of Erk signaling
represents a vulnerability and, potentially, a class of therapeutic
targets in human pre-B ALL. Targeting negative regulation of Erk
signaling for the treatment of pre-B ALL seems counterintuitive
because it represents effectively the opposite of current efforts
of targeted inhibition of oncogenic signaling. Besides the devel-
opment ofmore potent TKI (Cortes et al., 2013), recent therapeu-
tic concepts proposed the use of MEK inhibitors (Irving et al.,
2014) to attenuate oncogenic Erk signaling in pre-B ALL. Our
data using genetic mouse models and a small molecule inhibitor
targeting DUSP6 demonstrate an unexpected addiction of pre-B
ALL cells to Erk negative control. Normal cells lacking hyperac-
tive Erk signaling are less dependent on negative feedback
control of Erk and are spared, e.g., when treated with a small
molecule inhibitor of DUSP6. If validated in pre-clinical studies,
our approach of pharmacological blockade of Erk negative
feedback control may result in the development of multiple
targets for the therapy of pre-B ALL expressing hyperactive
Erk (e.g., lesions in NRAS, KRAS, BRAF, NF1, and PTPN11;
Zhang et al., 2011) and will broaden currently available treatment
options.e p value was calculated by t test for the S phase.
illion Spry2fl/fl pre-B ALL cells carrying either 4-OHT inducible Cre or an EV that
/SCID recipient mice (n = 14). The equal luciferase signal intensities for Cre and
pendent deletion of Spry2 prolonged survival of the recipient mice (p = 0.044).
were stained with 2070-dichlorofluorescein (DCF) diacetate which labels cells
[ROS] are depicted. The p values were calculated by t test.
-B ALL cells were plated in methylcellulose for 10 days and morphology and
were calculated by t test.
in the presence of IL7. After the expansion ofDusp6/ andDusp6+/+ pre-B cells,
In the presence of Imatinib, percentagesof BCR-ABL1GFP+ cells did not change.
lotted forDusp6+/+ andDusp6/pre-Bcells as fold-change relative tobaseline.
lls.
ith and without activation of Cre. All of the error bars represent SD. See also
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Figure 5. Pharmacological Inhibition of DUSP6-Mediated Erk Negative Control in Human Pre-B ALL Cells
(A) Chemical structure of selective DUSP6 inhibitor BCI.
(B) Time course analyses of BCI-treated patient-derived Ph+ ALL cells (BLQ5) were performed for ERK1/2-pT202/Y204, total ERK1/2, p38apT180/Y182, and total
p38a using b-actin as loading control.
(C) Time course analyses of BCI-treated patient-derived Ph+ ALL cells were performed for JNK1pT183/Y185 and total JNK1 using b-actin as loading control.
(D and E) Time course analyses of BCI-treated patient-derived Ph+ pre-B ALL cells for ERK1/2 and p38a activity (D) and intracellular levels of ROS using 2070-
dichlorofluorescein (DCF) diacetate (E).
(F) The effects of BCI on global phosphotyrosine.
(G) The effects of BCI on total and phosphorylated BCR-ABL1 and RPS6 as indicated.
(H) A dose-response analysis for BCI treatment and effects in viability of human Ph+ ALL cells with or without combination with 0.5 mmol/l Imatinib was performed.
The error bars represent SD.A likely limitation of our proposed concept will be the develop-
ment of drug-resistance. Current treatment regimens based on
TKI or MEK inhibitors alone invariably select for drug-resistant
subclones (Zabriskie et al., 2014). We expect that inhibitors of
Erk negative control (e.g., DUSP6 inhibition by BCI) will likewise
select for subclones that have acquired fitness to evade toxicity.
However, we predict that the outcome of clonal selection will not
confer adaptive fitness when selective pressures from opposite
directions are applied sequentially. For instance, if a sequential
treatment regimen begins with targeted inhibition of oncogene
signaling (e.g., TKI or MEK inhibitor), leukemia cells may adapt
to low oncogene signaling output by lowering the buffer setpoint124 Cancer Cell 28, 114–128, July 13, 2015 ª2015 Elsevier Inc.for negative control. In this case, washout of TKI or MEK inhibitor
and a subsequent round of pharmacological inhibition of nega-
tive control (e.g., using the DUSP6 inhibitor BCI) had more pro-
found effects because selective pressures in the first round of
treatment (TKI or MEK-inhibitor) did not confer adaptive fitness
in the second treatment cycle (DUSP6 inhibitor BCI). While
detailed studies are needed to optimize dosing and scheduling
of MEK inhibitors and BCI in an in vivo setting, these findings
suggest that pharmacological blockade of Erk negative control
represents a therapeutic concept that complements existing
kinase inhibitor-based approaches. Moreover, the sequential
use of pharmacological inhibition and hyperactivation of Erk
Figure 6. Pharmacological Inhibition of DUSP6 Induces Accumulation of ROS, Activation of DNA Damage Sensors, and Checkpoint Control
Molecules in Ph+ ALL Cells
(A) Ph+ ALL cells from five patients were treated with 5 mmol/l BCI for 12 hr and were analyzed by western blot for expression of Arf and p53 expression using
b-actin as loading control.
(B) Arf and p53 protein levels were compared by western blot in Dusp6+/+ and Dusp6/ pre-B ALL cells using b-actin as loading control.
(C) Cdkn2afl/fl and Trp53fl/fl pre-B ALL cells carrying either 4-OHT inducible Cre or an EV were treated with 4-OHT, then with BCI for 2 days, and cell viability was
measured by flow cytometry.
(D) Ph+ ALL cells from two patients were treated with 5 mmol/l BCI for 12 hr and total and phosphorylated proteins as indicated were measured by western blot.
(E) Ph+ ALL cells from five patients were treated with BCI or a combination of BCI and ROS-quencher catalase. The changes of viability comparing to the un-
treated cells were plotted on the y axis. The p value was calculated by t test.
(F) Normal bone marrow pre-B cells and primary Ph+ ALL cells were studied for expression and phosphorylation levels of p47phox (S359).
(G) Ncf1+/+ and Ncf1/ pre-B ALL cells were treated with BCI for 2 days and intracellular ROS levels were measured by flow cytometry.
(H) Ncf1+/+ and Ncf1/ pre-B ALL cells were treated with or without BCI for 2 days and viability changes relative to baseline (set as 100 percent; n = 3) were
measured by flow cytometry. The error bars represent SD. The p value was calculated by t test. See also Figure S4.may be useful to obviate clonal evolution that would otherwise
favor outgrowth of drug-resistant mutants.EXPERIMENTAL PROCEDURES
Mouse Model for BCR-ABL1- and NRASG12D Pre-B ALL
Bone marrow cells from young age-matched mice were harvested and retro-
virally transformed by BCR-ABL1 or NRASG12D in the presence of 10 ng IL7/ml(Peprotech). A summary of mouse strains used in this study and the detailed
procedure for bone marrow extraction and retroviral transduction is described
in Supplemental Information.
In Vivo Model for BCR-ABL1-Transformed ALL
BCR-ABL1-transformed ALL cells or human primary leukemia cells
were labeled with a firefly luciferase and were injected via tail vein into
sublethally irradiated NOD/SCID mice. Bioimaging of leukemia progression
in mice was performed at different time points using an in vivo IVIS 100Cancer Cell 28, 114–128, July 13, 2015 ª2015 Elsevier Inc. 125
Figure 7. Small Molecule Inhibition of DUSP6 Overcomes TKI-Resistance in Ph+ ALL Cells
(A) Summary and representative mutations common between and unique to LAX7 and LAX7R identified by whole exome sequencing.
(B) Chromatogram showing the absence and the presence of the KRASG12V mutation in LAX7 and LAX7R cells, respectively, and western blot showing
biochemical effects of BCI treatment on Erk activity.
(C) Viability of LAX7 and LAX7R cells incubated with BCI at various concentrations for 72 hr.
(D and E) Patient-derived Ph+ ALL cells growing in the presence of the control vehicle (control) or PD0325901 and washout of PD0325901 (Erk rebound) were
treated for 2 days with BCI at various concentrations and their viability wasmeasured by cell viability assay (D) or flow cytometry (E). The p values were calculated
by t test.
(legend continued on next page)
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bioluminescence/optical imaging system (Xenogen). More details on in vivo in-
jection and bioimaging are provided in the Supplemental Information. All
mouse experiments were subject to institutional approval by the University
of California San Francisco Institutional Animal Care and Use Committee. Pa-
tient derived leukemia samples were collected with informed consent from all
participants according to National Cancer Institute/Cancer Therapy Evaluation
Program (NCI/CTEP) approved protocol ECOG E2993T5 and studied with
approval of the Institutional Review Boards of the University of California
San Francisco (UCSF).
Proteomic Profiling
Proteomic profiling was performed using RPPA on peripheral blood and bone
marrow specimens from 192 patients with ALL, including 192 samples at diag-
nosis and 12 paired diagnosis-relapse samples evaluated at The University
of Texas M.D. Anderson Cancer Center (MDACC) between 1983 and 2007
(two from the 1980s and 45 from the 1990s). More details on the samples
and the RPPA protocol are provided in the Supplemental Information.
Statistical Analysis
All pairwise comparisons between the means were calculated by two-tailed
t test or Wilcoxon’s rank-sum test using R software (R Development Core
Team 2009; http://www.r-project.org). Comparison of patient survival data
was carried out using log-rank test. A confidence coefficient of 0.05 was
used for the all tests.
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